

**Richard W Horobin declares the following
presentation, entitled
In situ imaging of tumors using smart probes – are
they as smart as people think?
his intellectual property. You are entitled to copy
and distribute this presentation as long as:**


**The author is credited and the source cited — Slides
are not used commercially — No modifications
of the slides are made.**

© Richard Horobin, 2018




In situ imaging of tumors using “smart probes”— are they as smart as people think?


Richard W Horobin
Chemical Biology, School of Chemistry
University of Glasgow
Scotland UK



“In situ tumor imaging”?
Just what are we talking about here?



Lee et al 2014



Ntziachristos et al 2003

What clinical applications are envisaged for in vivo tumor imaging?

For diagnosis


For guiding surgery


For monitoring chemotherapy

What are “smart probes”?


And, more particularly, what kinds of smart probes are we concerned with today?

Small-molecule fluorescent compounds with the ability to target biochemically or metabolically anomalous tumor cells in a live animal.





A targeting moiety



A fluorescent moiety

Typical development protocol for a novel “smart probe”


1. Have an idea, synthesize a novel probe.
2. In cell culture, check if the probe binds with cancer cells & does not bind to non-transformed cells. If probe *is* selective for cancer cells ...
3. Check if the probe binds to experimental tumors in a lab rodent.
4. If yes ... publish.




No comments on
steps 1 & 2

Blood vessels of the circulatory system


Endothelial
cells lining
the blood
vessels




Blood vessels of the circulatory system




Blood vessels of the circulatory system




Blood vessels of the circulatory system



Blood vessels of the circulatory system



Blood vessels of the circulatory system



**Probe accumulation in a tumor
is favoured by
enhanced permeability
and retention**

This effect is **additional** to any
“smart targeting”.

How do probe properties influence enhanced *permeability*?

High water solubility



Strong binding to proteins



Strong binding to cells



How do probe properties influence enhanced *retention*?

Slow diffusion in free solution



Strong binding to proteins



Strong binding to cells



Distinguishing effective from ineffective probes — building & testing a simplistic model



Assuming enhanced permeability & retention


1. Assume diffusion and protein binding of probes are both important factors.
2. Assume rate depends on overall molecular size; and protein binding depends on aromatic system size.
3. Model overall & aromatic system sizes by molecular weight and conjugated bond number respectively.


Distinguishing effective from ineffective probes — building & testing a simplistic model


Assuming enhanced permeability & retention


4. Identify a set of **nonsmart** probes which accumulates in tumors, and another set which does not.
5. Plot these sets on a MW-CBN diagram.
6. If the model is valid, the two sets should fall in different parts of the diagram.












Now we have seen that “smart” probes fall into the same region of the plot as **not-smart tumor-localizing dyes and probes.**

This implies that localization of smart probes is due to both their “smartness” *and* to the enhanced permeability and retention effect.


**So does this mean that smart probes
are in fact not “smart”?**

**No, since “smartness” ensures that probes
are located on or inside tumor cells, not
merely within the tumor.**

So maybe we should say that “smart probes” are actually *smarter* than was thought? Or, at least smarter than the chemists who made them had thought?







Blood vessels of the circulatory system

